Australia·Stock·ASX (Australia)Pro Medicus Limited (PME.AX)
Health Care · Health Information Services · Asia-Pacific
Price in AUD, last 5 years
- Last price
- A$193.42 (Oct 22, 2026)
- 1-year return
- -31.7%
- 3-year annual return
- +35.7%
- 5-year annual return
- +29.3%
- 1-year volatility
- 54.6%
- Max drawdown (5Y)
- -67.2%
- Market cap (approx.)
- US$14.2B
- History available
- since Jan 2, 2014
About Pro Medicus Limited
Pro Medicus Limited (PME.AX) is a stock from Australia that trades on ASX (Australia) in AUD. It operates in the health care sector, Health Information Services industry. It's part of the S&P/ASX 50.
Over the last year its price fell 31.7% in AUD, with annual volatility of 55%: a quite volatile asset. Its worst drop over the last five years was 67.2% from a peak.
If your currency isn't the AUD, your real return will also depend on the exchange rate. In the optimizer you can choose your currency (USD, EUR, MXN, BRL, CLP, COP, PEN or ARS) and the calculation includes that currency risk.
How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.
Other health care assets in Asia-Pacific
| Asset | 1 year | 1Y return | Volatility | Market cap | |
|---|---|---|---|---|---|
 WuXi AppTec Co., Ltd.2359.HK · Stock · Health Care | +76.6% | 44% | US$71.3B | ||
 Chugai Pharmaceutical Co., Ltd.4519.T · Stock · Health Care | -6.0% | 40% | US$69.2B | ||
CSL LimitedCSL.AX · Stock · Health Care | -8.8% | 41% | US$66.0B | ||
Takeda Pharmaceutical Company Limited4502.T · Stock · Health Care | +53.0% | 23% | US$64.5B | ||
HOYA Corporation7741.T · Stock · Health Care | +15.3% | 30% | US$56.0B | ||
 Samsung Biologics Co.,Ltd.207940.KS · Stock · Health Care | -24.5% | 43% | US$47.8B | ||
 Sun Pharmaceutical Industries LimitedSUNPHARMA.NS · Stock · Health Care | +4.9% | 19% | US$44.5B | ||
ResMed Inc.RMD.AX · Stock · Health Care | -14.8% | 30% | US$34.3B |
Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.